Oral ganciclovir in pediatric transplant recipients: A pharmacokinetic study

Clinical Transplantation

Volumn 11, Issue 6, 1997, Pages 613-617

  Pescovitz, Mark D ^a   Brook, Bonnie ^a   Jindal, Rahul M ^a   Leapman, Stephen B ^a   Milgrom, Martin L ^a   Filo, Ronald S ^a  

^a INDIANA UNIVERSITY   (United States)

Author keywords

Children; Kidney; Liver; Oral ganciclovir; Transplantation

Indexed keywords

ANTIVIRUS AGENT; CYTOMEGALOVIRUS ANTIBODY; GANCICLOVIR; IMMUNOGLOBULIN M;

ADOLESCENT; ARTICLE; CHILD; CLINICAL ARTICLE; CYTOMEGALOVIRUS INFECTION; DRUG TOLERABILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INFANT; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; ORAL DRUG ADMINISTRATION; PRESCHOOL CHILD; PRIORITY JOURNAL; RECIPIENT; SCHOOL CHILD;

ADMINISTRATION, ORAL; ADOLESCENT; ANTIVIRAL AGENTS; AREA UNDER CURVE; CHILD; CHILD, PRESCHOOL; CYTOMEGALOVIRUS INFECTIONS; GANCICLOVIR; HUMANS; INFANT; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; OPPORTUNISTIC INFECTIONS;

EID: 0030706179     PISSN: 09020063     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. HIBBERD PL, RUBIN RH. Prevention of cytomegalovirus infection in the pediatric renal transplant recipient. Pediatr Nephrol 1991: 5: 112.
2. BURD RS, GILLINGHAM KJ, FARBER MS, et al. Diagnosis and treatment of cytomegalovirus disease in pediatric renal transplant recipients. J Pediatr Surg 1994: 29: 1049.
3. PATEL R, SNYDMAN DR, RUBIN RH, et al. Cytomegalovirus prophylaxis in solid organ transplant recipients. Transplantation 1996: 61: 1279.
4. MERIGAN TC, RENLUND DG, KEAY S, BRISTOW MR, STAMES V, O'CONNELL JB. A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation. N Engl J Med 1992: 326: 1182.
5. STRATTA RJ, SHAEFER MS, CUSHING KA, et al. Successful prophylaxis of cytomegalovirus disease after primary CMV exposure in liver transplant recipients. Transplant 1991: 51: 90.
6. CRUMPACKER CS. Ganciclovir. N Engl J Med 1996: 335: 721.
7. DREW WL, IVES D, LALEZARI J, et al. Oral ganciclovir as maintenance treatment for cytomegalovirus retinitis in patients with AIDS. N Engl J Med 1995: 333: 615.
8. SPECTOR SA, BUSCH DF, FOLLANSBEE S, et al. Pharmacokinetic, safety, and antiviral profiles of oral ganciclovir in persons infected with human immunodeficiency virus: a phase I/II study. J Infect Dis 1995: 171: 1431.
9. DREW WL, MINER R, SALEH E. Antiviral susceptibility testing of cytomegalovirus: criteria for detecting resistance to antivirals. Clin Diagnost Virol 1993: 1: 179.
10. PLOTKIN SA, DREW WA, FELSENSTEIN D, HIRSCH MS. Sensitivity of clinical isolates of human cytomegalovirus to 9-(1,2-dihydroxy-2-propoxymethyl)guanine. J Infect Dis 1985: 152: 833.
11. PAGE T, SHERWOOD C, CONNOR JD, TARNOWSKI T. Simple reversed-phase high-performance liquid chromatography quantitation of ganciclovir in human serum and urine. J Chromatogr B 1996: 675: 342.
12. TRANG JM, KIDD L, GRUBER W, et al. Linear single-dose pharmacokinetics of ganciclovir in newborns with congenital cytomegalovirus infections. Clin Pharmacol Ther 1993: 53: 15.
13. ANDERSON RD, GAINES K, JUNG D, DORR A, HULSE JD, SMITH RB. Ganciclovir absolute bioavailability and steadystate pharmacokinetics after oral administration of two 3000-mg/d dosing regimens in human immunodeficiency virus- and cytomegalovirus-seropositive patients. Clin Therap 1995: 17: 425.
14. HOPPU K, KOSKIMIES O, HOLMBERG C, HIRVISALO EL. Pharmacokinetically determined cyclosporine dosage in young children. Pediatr Nephrol 1991: 5: 1.
15. YUEN GJ, DRUSANO GL, FLETCHER C, et al. Population differences in ganciclovir clearance as determined by nonlinear mixed-effects modeling. Anitmicrob Agents Chemo 1995: 39: 2350.
16. DREWE J, BEGLINGER C, KISSEL T. The absorption site of cyclosporin in the human gastrointestinal tract. Br J Clin Pharmacol 1992: 33: 39.
17. SPECTOR SA, MCKINLEY GF, LALEZARI JP, et al. Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS. N Engl J Med 1996: 334: 1491